+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain

The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain

Neurobiology of Disease 20(2): 541-549

This work examines whether administering the F(ab' )2 fragment of an IgG1 monoclonal antibody (mAb) targeting the N-terminal 1-13 amino acids of the beta-amyloid peptide (Abeta mAb) reduces amyloid deposition in Alzheimer's disease (AD). The F(ab')2 fragment was injected intraperitoneally or intracranially into Tg2576 mice, a murine model of human AD. Both routes of administration significantly reduced Abeta plaque formation in the brain, as determined immunohistochemically and by monitoring levels of Abeta1-40 and Abeta1-42 peptide. Use of the F(ab')2 fragment significantly reduced phagocytic infiltration in the CNS when compared to intact mAb. Since IgG1 Abs do not fix complement, these findings suggest that effective in vivo clearance of amyloid deposits can be achieved without stimulation of FcR-reactive phagocytes or activation of the complement cascade.

(PDF emailed within 0-6 h: $19.90)

Accession: 050535666

Download citation: RISBibTeXText

PMID: 15908227

DOI: 10.1016/j.nbd.2005.04.007

Related references

Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. Journal of Neuroscience 29(36): 11393-8, 2009

Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain. Molecular and Cellular Neurosciences 15(2): 183-198, 2000

Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response. Journal of the Neurological Sciences 272(1-2): 87-98, 2008

Abeta immunization in aged vervet monkeys reduces Abeta levels in brain and CSF. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 133 5, 2003

Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases Abeta burden in a mouse model of Alzheimers disease. Society for Neuroscience Abstracts 27(2): 1806, 2001

Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. Journal of Neuroscience 31(6): 2313-2320, 2011

Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. Journal of Neuroscience 27(32): 8628-8635, 2007

Anti - Abeta antibody age - dependent systemic effects on transport of Abeta into and out of the brain in tg 2576 mice. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 667 3, 2003

Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. Vaccine 24(15): 2824-2834, 2006

Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. Journal of Biological Chemistry 281(7): 4292-4299, 2005

Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. Journal of Neuroscience 26(18): 4717-4728, 2006

Plasma Abeta levels in young APP v717f transgenic mice following anti - Abeta antibody administration predict brain amyloid burden at an older age. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 842 19, 2003

Passive immunization with an anti abeta antibody rapidly reverses memory impairment but not brain abeta burden in a mouse model of alzheimers disease. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 685 5, 2002

A comparative analysis of brain and plasma Abeta levels in eight common non-transgenic mouse strains: validation of a specific immunoassay for total rodent Abeta. Current Alzheimer Research 4(3): 297-303, 2007